Damora Therapeutics, Inc.
DMRA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001800315
In the last 90 days, Damora Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 104 institutions reported holding it in 13F filings for Q2 2026, worth $1.67B in total; Viking Global Investors is the only superinvestor holding it.
13F holders, Q4 2025
Institutional positions in Damora Therapeutics, Inc. as of Dec 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 18
- +6 vs. Q3 2025
- Shares held
- 1.11M
- +937.7K (+550.9%) vs. Q3 2025
- Total value
- $65.5M
- +$64.8M (+10,236.9%) vs. Q3 2025
- New holders
- 12
- 3 more added
- Sold out
- 6
- 3 more reduced
Compare with Q3 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DMRA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 104 | $1.67B |
| Q1 2026 | 65 | $1.45B |
| Q4 2025 | 18 | $65.5M |
| Q3 2025 | 12 | $633.3K |
| Q2 2025 | 9 | $451.5K |
| Q1 2025 | 11 | $442.4K |
| Q4 2024 | 10 | $660.7K |
| Q3 2024 | 10 | $1.56M |
| Q2 2024 | 22 | $1.91M |
| Q1 2024 | 26 | $3.09M |
| Q4 2023 | 22 | $2.77M |
| Q3 2023 | 22 | $3.92M |
| Q2 2023 | 27 | $25.7M |
| Q1 2023 | 26 | $17.8M |
| Q4 2022 | 22 | $10.2M |
| Q3 2022 | 26 | $17.3M |
| Q2 2022 | 23 | $15.7M |
| Q1 2022 | 25 | $21.0M |
| Q4 2021 | 26 | $30.5M |
| Q3 2021 | 25 | $37.2M |
| Q2 2021 | 27 | $57.4M |
| Q1 2021 | 19 | $82.9M |
Institutions, Q4 2025
Shares, value and share of portfolio for each institution holding Damora Therapeutics, Inc.; share changes are against Q3 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| SBI Securities Co., Ltd. | 14 | $322 | 0.00% | −4−22.2% | Reduced |
| SHP Wealth Management | 25 | $575 | 0.00% | +25 | New |
| Tower Research Capital LLC (TRC) | 176 | $4.05K | 0.00% | −1,251−87.7% | Reduced |
| Citigroup Inc | 1,127 | $25.9K | 0.00% | +1,084+2,520.9% | Added |
| Bank of America Corp | 1,228 | $28.3K | 0.00% | −5,272−81.1% | Reduced |
| UBS Group AG | 6,389 | $147.0K | 0.00% | +6,330+10,728.8% | Added |
| BlackRock, Inc. | 7,520 | $173.0K | 0.00% | +7,420+7,420.0% | Added |
| Geode Capital Management, LLC | 11,573 | $266.3K | 0.00% | +11,573 | New |
| Sigma Planning Corp | 14,500 | $333.6K | 0.01% | +14,500 | New |
| Vanguard Group Inc | 18,247 | $419.9K | 0.00% | +18,247 | New |
| Morgan Stanley | 74,917 | $1.72M | 0.00% | +74,917 | New |
| Boothbay Fund Management, LLC | 95,798 | $2.20M | 0.06% | +95,798 | New |
| Point72 Asset Management, L.P. | 109,000 | $2.51M | 0.00% | +109,000 | New |
| Remedium Capital Partners, LLC | 120,473 | $2.77M | 1.63% | +120,473 | New |
| Jain Global LLC | 120,566 | $2.77M | 0.03% | +120,566 | New |
| FMR LLC | 238,878 | $5.50M | 0.00% | +238,878 | New |
| Ikarian Capital, LLC | 285,710 | $6.57M | 0.85% | +285,710 | New |
| Janus Henderson Group PLC | 1,739 | $40.0M | 0.02% | +1,739 | New |
| Novo Holdings A/S | 0 | $0 | 0.00% | −86,579−100.0% | Sold out |
| Connective Capital Management, LLC | 0 | $0 | 0.00% | −26,956−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −20,296−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −15,044−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −13,128−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −55−100.0% | Sold out |